Bluechiip Limited (ASX:BCT) (FRA:1BL), a developer and leader in wireless tracking solutions for the healthcare and life science, security, defence and manufacturing industries is pleased to release its Appendix 4C - Quarterly Cashflow report and update for the quarter ended 30 June 2021.
Bluechiip Ltd (ASX:BCT) understands that every sample - stem cells, blood, eggs, sperm and other biospecimens - is critical, so our objective is to manage each one with optimal quality in the most efficient way. Bluechiip's advanced management solution is the only one that provides sample temperature with ID in cryogenic environments to. Most importantly, this delivers confidence in every sample.
Bluechiip's unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels (hand-written and pre-printed), barcodes (linear and 2D), and Radio Frequency Identification. Bluechiip tags are either embedded or manufactured into storage products such as vials or bags. Each product can be easily identified, and critical information such as sample temperature, is detected by readers and stored in the Bluechiip software. In addition to functioning in extreme temperatures, the Bluechiip(R) Advanced Sample management solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.
Bluechiip's technology has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.
Bluechiip: Delivering confidence in every sample.
Bluechiip Ltd (ASX:BCT) (FRA:1BL) provides an Open Briefing interview with MD Andrew McLellan. In this Open Briefing.
Bluechiip Ltd (ASX:BCT) (FRA:1BL) and Labcon are happy to announce a mutually-beneficial resolution to their disputes as set forth in the litigation filed in the United States District Court for the Northern District of California.
The International Society for Biological and Environmental Repositories (ISBER) - the leading network in the global biobanking and biorepository community - announced today that Australian company Bluechiip Ltd's (ASX:BCT) BoxTracker(TM) has won the 2021 Outstanding New Product Award.
Bluechiip Ltd (ASX:BCT) Lodgement of Open Briefing - Managing Director, Andrew McLellan: Bluechiip's results for Q3FY21; pipeline developments; direct to market strategy.
Bluechiip Limited (ASX:BCT), a developer and leader in wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries is pleased to release its Appendix 4C - Quarterly Cashflow report and update for the quarter ended 31 March 2021.
Bluechiip Limited (ASX:BCT), a leader in the development of sample tracking technology for harsh environments, today announced that it has received $1.62M Research and Development Tax Incentive Refund from the Australian Tax Office for the financial year ended 30 June 2020.
The principal activity of Bluechiip Ltd (ASX:BCT) during the half-year was the development and commercialisation of a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries.
Bluechiip Ltd (ASX:BCT) sales and marketing teams both in Australia and the United States continue to make progressive negotiations with potential OEMs especially in the IVF and Cell Therapy markets despite current COVID-19 travel restrictions.
Bluechiip Ltd (ASX:BCT) has a world first, highly differentiated technology, with protected IP and a $200M growing target market, with very large adjacent markets.